LUNG CANCER RESEARCH FOUNDATION

Living. Breathing. Science.

aka LCRF | New York, NY | https://www.lcrf.org/

Donate

GuideStar Charity Check

EIN: 14-1935776

Contributions tax deductible
as of March 2023

IRS BMF 509(a)(1)
as of March 13, 2023

View summary

Charity Check report

Mission

The mission of the Lung Cancer Research Foundation is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer.

Ruling year info

2005

Executive Director

Dennis Chillemi

Main address

501 Seventh Avenue Suite 401

New York, NY 10018 USA

Show more contact info

EIN

14-1935776

Subject area info

Foundations

Respiratory system diseases

Lung cancer

Science

Population served info

Adults

NTEE code info

Private Grantmaking Foundations (T20)

IRS subsection

501(c)(3) Public Charity

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Tax forms

Show Forms 990

Communication

Programs and results

Reports and documents

What we aim to solve

SOURCE: Self-reported by organization

Despite the fact that lung cancer is the leading cause of cancer death worldwide, it receives far less funding than other types of cancer. The Lung Cancer Research Foundation (LCRF) is helping to close this gap, bringing hope to people with lung cancer. LCRF’s mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer. Lung cancer research has made steady progress over the past decade, leading to improved patient outcomes. Through the notable achievements of our investigators and our diverse portfolio of scientific research projects, LCRF has contributed to this remarkable progress. We are at a pivotal time to accelerate support for research across all areas of unmet need. The progress being made is remarkable and is resulting in increased survival rates for certain lung cancer patients. Through our investments in scientific research, we are well on our way to bringing these improvements to all lung cancer patients.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Scientific Grant Program

Despite being the leading cause of cancer mortality, lung cancer receives far less research funding per death. Lung cancer receives $2,462 per death compared to breast cancer at $16,405, prostate cancer at $7,469, and pancreatic cancer at $4,326. That is why funding from non-governmental organizations is so critical. The Lung Cancer Research Foundation (LCRF) plays a pivotal role in this funding landscape, supporting early-career investigators who, if not for our funding, may not receive funding at all.

Since 2005, The Lung Cancer Research Foundation, and its progenitor organizations, has been committed to funding cutting edge research that transforms the lung cancer treatment landscape. When we first opened our doors, our mission was simple: provide hope by funding the best research and help bring it to people. We have been wildly successful. In 15 years, we have become one of the largest private funders of lung cancer research— enabling earlier detection, deeper understanding of the mechanisms that allow lung cancer to form, and new and expanded treatment options that have saved many lives. Simultaneously, our Scientific Advisory Board has become one of the preeminent bodies in the lung cancer research community. Furthermore, our investment in early career investigators continues to allow new talent to thrive and grow in the space as is demonstrated through follow-on funding many have received since receiving their LCRF grant.

To date, LCRF has provided 383 research grants totaling nearly $36 million, the largest amount provided by a non-governmental organization dedicated to funding lung cancer research. The support within the patient community, researchers, strategic partners, and industry partners is key to our present successes as well as achieving our future vision to find an eventual cure for lung cancer.

During 2020 we funded eight (8) research grants for two years at $150,000 each. Four (4) research grants were funded through the LCRF Pilot Grant Program which funds innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, and research focused on a myriad of topics. The projects funded span three countries and topics including:
• Identifying risk factors for lung cancer predisposition through systematic evaluation of environmental carcinogens’ activation by the respiratory tract microbiota
• SNF2 Histone Linker PHD RING Helicase as a novel tumor suppressor gene and risk factor in lung adenocarcinoma development
• Targeting the IL-1beta pathway for lung cancer treatment
• Targeting APOBEC3A induction as a new therapeutic strategy to prevent acquired drug resistance in non-small cell lung cancer.
An additional four (4) research grants were funded through the LCRF Disparities in Lung Cancer Program which funds research that addresses certain disparities that include but are not limited to race and gender-dependent differences; social and biological risk factors; never smokers; equity and access to health care; and impacts of geography, age, and socioeconomic status on outcomes. The projects funded span two countries and topics including:
• Development of risk prediction models to ensure equitable eligibility for lung cancer screening in minority populations
• Understanding the immune landscape of non-small cell lung cancer in African Americans
• Contributions of tobacco exposure, NNK, and stress to lung cancer risk disparities between AA and CA male smokers
• Determining differences in immunotherapy outcomes and immunobiology in African American patients with NSCLC.
In addition to the direct research funding provided through the LCRF pilot and LCRF disparities grant tracks, the foundation is currently administrating research partnerships with Pfizer Global Medical Grants and the Lung Cancer Mutation Consortium.

The LCRF and Pfizer Global Medical collaboration to fund over $1 million in research grants through a Competitive Research Grant Program was started in 2019 and will continue through 2021. The research grant opportunity focused on understanding ways to improve clinical practices for side effect management for non-small cell lung cancer (NSCLC) patients receiving targeted therapies. This is the first collaboration of its kind in lung cancer and could have an impact on patient care. The collaboration between LCRF and Pfizer funded four (4) research grants covering topics such as:
• Real-time monitoring and modeling of symptoms and adverse events in lung cancer patients receiving oral targeted therapies for tumors with oncogenic driver mutations
• Development and implementation of 4R care sequences in patients with NSCLC receiving targeted therapies
• Implementation strategies for monitoring adherence in real-time (iSMART)
• Proactive monitoring of treatment-related adverse events through a mobile application in NSCLC patients treated with tyrosine kinase inhibitors: the “Empower Me” Digital Therapeutic Study.
LCRF’s partnership with the Lung Cancer Mutation Consortium (LCMC) dates back to 2011 covering three clinical trials. The LCMC2 clinical trial enrolled 1,000 patients via a network of fourteen (14) notable domestic clinical research sites. The clinical trial studied the Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations. The LCMC3 clinical trial began in 2017 and has enrolled 1,000 patients via a network of five (5) domestic clinical research sites. LCMC3 is designed as a neoadjuvant and adjuvant trial of immune checkpoint blockade for stage IB-IIIA non-small cell lung cancer. Final reporting from this clinical trial should be completed in alter 2021 or early 2022. Launched in late 2020, LCMC4 will be a study of 1,000 patients via a network of 25+ domestic clinical research sites. The goal of the clinical trial is to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early-stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer.

In 2020, our research investment was funded without the need for deficit spending, and we are poised to grow our research investment in the coming years.

Patient Education & Outreach

PATIENT EDUCATIONAL PORTFOLIO
The overall goal of the Lung Cancer Research Foundation (LCRF)’s Patient Educational Portfolio is to provide relevant and accurate information on lung cancer using patient-friendly language. Patients and caregivers need information at all steps in the continuum of care, from diagnosis through treatment and beyond. The Lung Cancer Research Foundation has a portfolio of educational resources to help patients and their families better understand lung cancer and learn about their treatment options. Helping patients to understand new treatments and the hope offered by these treatment advances are key objectives of our educational materials. We also have materials designed to educate the public about the magnitude of lung cancer as a health care problem and ways to identify symptoms of the disease.

In 2020, LCRF distributed over 70,000 educational materials to lung cancer patients, caregivers, advocates and healthcare professionals across the nation in both print and digital format. Our website also contains links to information and resources, which receives on average over 10,000 unique impressions annually. Our continued goal is to steadily increase our materials distributed, particularly with digital downloads as there has been a surge in demand for readily available information.

The key objectives of the portfolio are to:
• Increase awareness in the general public on the risks of lung cancer and lung cancer screening
• Increase patient and caregiver education on lung cancer treatment options for NSCLC and SCLC
• Engage patients and caregivers in discussion of lung cancer research and its influence on screening, treatment advances, and health outcomes
The Patient Educational Programs Review Committee (PEPRC) assists in the evaluation of materials used for LCRF’s patient support and educational programs, awareness campaigns, and other patient-facing initiatives. The PEPRC consists of multidisciplinary experts such as oncologists, researchers, nurses, social workers, and lung cancer patients/survivors. PEPRC also aids in shaping the overall strategy by lending their respective expertise in the field.

The Patient Educational Portfolio is also crafted with assistance from the feedback we receive from our community. Our materials are rated on average a 4.6/5 according to the feedback collected from individuals who download or order our print materials on our website. Sample feedback includes:

Thank you for providing free educational resources. I am a Thoracic Nurse Navigator and provide these to all of my lung cancer patients. My patients like and appreciate them very much.

Thank you so much for providing information to people trying to navigate a lung cancer diagnosis and all the stress related to the entire process.

My mother was recently diagnosed with lung cancer. Very heartbreaking and a surprise to us all. Heard nothing but good reviews about LCRF so I look forward to learning about everything and I appreciate what you all do.

LUNG CANCER SUPPORT LINE

Our Lung Cancer Support Line is a toll-free number (844)-835-4325, is available to anyone affected by lung cancer, primarily lung cancer patients and caregivers. The Support Line operates Monday-Friday 9am-5pm ET and is equipped with extensive and up-to-date resource guides for common needs and services for lung cancer patients such as financial assistance, transportation or lodging to/from medical appointments, support groups, and much more. Lung cancer patients and their caregivers may call or email the program as often as they wish, and the service is offered free of charge. The Lung Cancer Support Line helps fill an unmet need by providing personalized, one-on-one support to callers who are facing the challenges of lung cancer.

In 2020, we assisted over 400 lung cancer patients and caregivers through the Support Line. Approximately half of which are newly diagnosed patients or caregivers of those who are recently diagnosed, proving that the Support Line provides a timely service for those seeking support. The remainder of support line inquiries come in from healthcare institutions or community-based institutions looking for resources for their patients. Our continued goal for the Support Line is to strengthen our communication with those who are newly diagnosed and engaged in our educational programs. We also hope to increase our Support Line reach by 20% over the next year via targeted outreach and promotion of our services. Through the Support Line, we provide:

• A central hub for accessing emotional support, patient-specific local and national resources
• Accurate and up-to-date educational information and materials
• Patient/caregiver opportunities to connect with others through a peer matching program
• Engagement opportunities within the LCRF lung cancer community

#TOGETHERSEPARATELY SERIES

Lung cancer awareness, education, and advocacy suffers in comparison to some other diseases because of the poor prognosis as well as the stigma patients may face given the association with smoking. Advances in treatments, however, have given patients and caregivers new hope and many are interested in joining together to “make a difference” in their own lung cancer journey as well as in their broader community.

An important component of the #TogetherSeparately live virtual series is the ability of patients/survivors and caregivers to connect and re-connect with others who are living with lung cancer. We want patients to know that they are not alone and that we are working to support the lung cancer community. This live meeting format gives hope to participants through the opportunity to meet lung cancer researchers and speak to researchers about their concerns and needs. These needs became even more evident with the onset of the COVID-19 global pandemic in March 2020 that shaped the way we live and receive medical care. Many lung cancer patients expressed their feelings of isolation and desire for updates on current lung cancer and COVID-19 related information. This inspired the series to provide both a connect with the broader lung cancer community as well as to learn more about lung cancer related topics. By the end of each event in the series, new friendships have formed, information has been exchanged, and everyone—including us—leaves energized and inspired.

The learning objectives of the live virtual series are:
• Learn the fundamentals of lung cancer and treatment options
• Understand why funding research is crucial for the development of new therapies for patients
• Learn about programs and resources available to the lung cancer community

Since its inception in March 2020, we had almost 2,000 individuals register for at least one of our #TogetherSeparately events with an average attendance record of 40-60 individuals per webinar. The majority of the attendees in this series are lung cancer patients, survivors, advocates, caregivers, and community providers. Our goal is to continue the series and provide 10-12 webinars annually on a variety of topics related to living with lung cancer.

We also have a companion #TogetherSeparely Support Group on Facebook where constituents can deepen their connections with each other and have regular informational posts and resources shared with them. Currently, the Facebook group has 376 members and continues to grow every month. This active group has a steady engagement rate between 60-65% and we hope to grow this group to up to 800 members by the end of 2021.

Population(s) Served

Adults

Where we work

Affiliations & memberships

LUNG CANCER MUTATION CONSORTIUM 2008

External reviews

Direction of Success

Increasing

Context Notes

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

What is the organization aiming to accomplish?

LCRF is a nonprofit organization that provides critical funding to innovative research around the world focused on the prevention, diagnosis, and treatment of lung cancer. Through the Scientific Grant Program, LCRF supports the best and brightest researchers at universities and cancer centers throughout the country. Our grant platform is recognized as one of the most prestigious in the lung cancer field and is guided by an advisory panel of the country’s leading experts across all dimensions of research including lab based and clinical. he Foundation is committed to growing the grant program to help fuel the breakthroughs of tomorrow and fund more research with the potential to improve lung cancer outcomes.

The overall goal of the LCRF Scientific Grant Program is to fund innovative, high-reward research across the spectrum of basic, clinical, and translational research that has the potential to extend survival and quality of life for people with lung cancer.

What are the organization's key strategies for making this happen?

Our Scientific Grant Program support enables researchers with groundbreaking, innovative ideas and paves the way for follow-on funding from sources such as the National Cancer Institute (NCI)/National Institutes of Health (NIH) and the American Cancer Society.

The LCRF Scientific Advisory Board (SAB), comprised of renowned multi-disciplinary scientists and physicians, ensures that the most promising research is funded across a variety of topics including:
• Improved understanding of lung cancer biology
• Prevention and screening for early detection
• Identification of new biomarkers and the development of targeted therapies
• Development of more effective and less toxic therapies
• Psychosocial research including supportive measures for people with lung cancer and their families
• Quality of care and outcomes research

What are the organization's capabilities for doing this?

LCRF’s Scientific Advisory Board includes renowned scientists, physicians and thought leaders spanning a broad range of disciplines in lung cancer research. Many of the members are also affiliated with leading cancer centers in the United States.

The Scientific Advisory Board leverages its collective experience and expertise to maintain the objectivity of LCRF’s grant selection process and help ensure that the Foundation continues to fund innovative, high-reward research that might otherwise go uninvestigated.

What have they accomplished so far and what's next?

To date, LCRF has funded 394 research grants, totaling nearly $39 million, the highest amount provided by a nonprofit organization dedicated to funding lung cancer research.

How we listen

SOURCE: Self-reported by organization

Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.

We demonstrated a willingness to learn more by reviewing resources about feedback practice.

We shared information about our current feedback practices.

Who are the people you serve with your mission?

We serve lung cancer patients, caregivers, medical professionals, and researchers.
How is your organization collecting feedback from the people you serve?

Community meetings/Town halls, Suggestion box/email, We provide and [email protected] email address,
How is your organization using feedback from the people you serve?

To identify and remedy poor client service experiences, To identify bright spots and enhance positive service experiences, To make fundamental changes to our programs and/or operations, To inform the development of new programs/projects, To identify where we are less inclusive or equitable across demographic groups, To strengthen relationships with the people we serve, To understand people's needs and how we can help them achieve their goals,
What significant change resulted from feedback?

In response to the growing numbers of African Americans being diagnosed with lung cancer, we partnered with the African Methodist Episcopal Church (AME) to develop a series of patient education materials aimed specifically towards the African American community. The materials included a printed booklets that was distributed to many of the churches in the AME network and produced a public service announcement with Jesse Owens grandson urging members of the African American community to be screened for lung cancer. We also decided to continue our #Together Separately webcast/Town Hall meetings series. These virtual meetings started at the beginning of the Covid-19 pandemic to bring together lung cancer patients and are now a permanent part of our mission.
With whom is the organization sharing feedback?

The people we serve, Our staff, Our board, Our funders, Our community partners,
How has asking for feedback from the people you serve changed your relationship?

LCRF has always been a leader in funding lung cancer research and in recent years we have become a trusted source of information for the entire lung cancer community. We have worked very hard over the last three years to strengthen our relationships with lung cancer patients, caregivers, medical professionals, funders, and researchers.
Which of the following feedback practices does your organization routinely carry out?

We collect feedback from the people we serve at least annually, We take steps to get feedback from marginalized or under-represented people, We aim to collect feedback from as many people we serve as possible, We take steps to ensure people feel comfortable being honest with us, We look for patterns in feedback based on demographics (e.g., race, age, gender, etc.), We look for patterns in feedback based on people’s interactions with us (e.g., site, frequency of service, etc.), We engage the people who provide feedback in looking for ways we can improve in response, We act on the feedback we receive, We tell the people who gave us feedback how we acted on their feedback, We ask the people who gave us feedback how well they think we responded,
What challenges does the organization face when collecting feedback?

We don't have any major challenges to collecting feedback,

Financials

Financial data

Source: IRS Form 990

Digitizing IRS form 990 data

LUNG CANCER RESEARCH FOUNDATION

Revenue & expenses

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990

Fiscal year ending: Download Data

Revenue
Contributions	$948,959
Government Grants	$0
Program Services	$0
Investments	$25,644
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$974,603

Expenses
Program Services	$643,799
Administration	$116,838
Fundraising	$248,889
Total Expenses	$1,009,526
Net Gain/Loss	($34,923)

Functional expenses
Accounting Fees	$21,470
Advertising & Promotion	$0
Information Technology Expenses	$0
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$179,765

Revenue
Contributions	$902,165
Government Grants	$0
Program Services	$0
Investments	$9,849
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$912,014

Expenses
Program Services	$340,451
Administration	$152,725
Fundraising	$280,094
Total Expenses	$773,270
Net Gain/Loss	$138,744

Functional expenses
Accounting Fees	$21,579
Advertising & Promotion	$0
Information Technology Expenses	$0
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$195,627

Revenue
Contributions	$2,337,677
Government Grants	$0
Program Services	$0
Investments	($576)
Special Events	$406,533
Sales	$0
Other	$0
Total Revenue	$2,743,634

Expenses
Program Services	$890,975
Administration	$188,476
Fundraising	$107,740
Total Expenses	$1,187,191
Net Gain/Loss	$1,556,443

Functional expenses
Accounting Fees	$25,495
Advertising & Promotion	$0
Information Technology Expenses	$0
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$387,739
Government Grants	$0
Program Services	$0
Investments	$4,777
Special Events	$658,619
Sales	$0
Other	$0
Total Revenue	$1,051,135

Expenses
Program Services	$1,091,727
Administration	$344,191
Fundraising	$228,851
Total Expenses	$1,664,769
Net Gain/Loss	($613,634)

Functional expenses
Accounting Fees	$30,270
Advertising & Promotion	$0
Information Technology Expenses	$0
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$329,730
Government Grants	$0
Program Services	$0
Investments	$3,019
Special Events	$749,056
Sales	$0
Other	$0
Total Revenue	$1,081,805

Expenses
Program Services	$1,152,897
Administration	$236,842
Fundraising	$200,794
Total Expenses	$1,590,533
Net Gain/Loss	($508,728)

Functional expenses
Accounting Fees	$22,756
Advertising & Promotion	$0
Information Technology Expenses	$0
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$275
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$1,142,173
Government Grants	$0
Program Services	$0
Investments	$2,858
Special Events	$191,659
Sales	$0
Other	$0
Total Revenue	$1,336,690

Expenses
Program Services	$970,167
Administration	$272,983
Fundraising	$301,482
Total Expenses	$1,544,632
Net Gain/Loss	($207,942)

Functional expenses
Accounting Fees	$26,606
Advertising & Promotion	$0
Information Technology Expenses	$0
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$5,215
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$1,658,863
Government Grants	$0
Program Services	$0
Investments	$2,358
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$1,661,221

Expenses
Program Services	$1,188,406
Administration	$270,539
Fundraising	$295,842
Total Expenses	$1,754,787
Net Gain/Loss	($93,566)

Functional expenses
Accounting Fees	$31,109
Advertising & Promotion	$0
Information Technology Expenses	$0
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$12,339
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$3,745,414
Government Grants	$0
Program Services	$0
Investments	($4,888)
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$3,740,526

Expenses
Program Services	$2,868,830
Administration	$246,577
Fundraising	$438,870
Total Expenses	$3,554,277
Net Gain/Loss	$186,249

Functional expenses
Accounting Fees	$111,121
Advertising & Promotion	$0
Information Technology Expenses	$0
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$22,559
Pension Plan Contributions	$21,269
Professional Fundraising Expenses	$0

Revenue
Contributions	$3,695,552
Government Grants	$0
Program Services	$0
Investments	$2,519
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$3,698,071

Expenses
Program Services	$3,400,404
Administration	$268,748
Fundraising	$517,848
Total Expenses	$4,187,000
Net Gain/Loss	($488,929)

Functional expenses
Accounting Fees	$34,168
Advertising & Promotion	$0
Information Technology Expenses	$64,774
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$60,514
Pension Plan Contributions	$36,038
Professional Fundraising Expenses	$0

Revenue
Contributions	$4,561,443
Government Grants	$0
Program Services	$0
Investments	$41,046
Special Events	$4,387
Sales	$0
Other	$26,619
Total Revenue	$4,633,495

Expenses
Program Services	$3,744,760
Administration	$289,840
Fundraising	$519,646
Total Expenses	$4,554,246
Net Gain/Loss	$79,249

Functional expenses
Accounting Fees	$28,788
Advertising & Promotion	$0
Information Technology Expenses	$75,300
Insurance Expenses	$0
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$98,008
Pension Plan Contributions	$52,200
Professional Fundraising Expenses	$0

Revenue
Contributions	$6,296,669
Government Grants	$0
Program Services	$0
Investments	($19,976)
Special Events	($778,064)
Sales	$0
Other	$25,949
Total Revenue	$5,524,578

Expenses
Program Services	$5,068,402
Administration	$345,690
Fundraising	$912,619
Total Expenses	$6,326,711
Net Gain/Loss	($802,133)

Functional expenses
Accounting Fees	$38,494
Advertising & Promotion	$0
Information Technology Expenses	$149,335
Insurance Expenses	$16,832
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$78,673
Pension Plan Contributions	$71,126
Professional Fundraising Expenses	$0

Revenue
Contributions	$5,916,763
Government Grants	$0
Program Services	$0
Investments	$3,178
Special Events	($591,417)
Sales	$0
Other	$9,182
Total Revenue	$5,337,706

Expenses
Program Services	$4,330,353
Administration	$356,133
Fundraising	$852,288
Total Expenses	$5,538,774
Net Gain/Loss	($201,068)

Functional expenses
Accounting Fees	$31,070
Advertising & Promotion	$0
Information Technology Expenses	$206,873
Insurance Expenses	$22,336
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$4,292
Pension Plan Contributions	$80,691
Professional Fundraising Expenses	$0

Revenue
Contributions	$5,023,193
Government Grants	$442,500
Program Services	$0
Investments	$1,357
Special Events	($189,312)
Sales	$0
Other	$34,702
Total Revenue	$5,312,440

Expenses
Program Services	$3,859,971
Administration	$321,734
Fundraising	$846,314
Total Expenses	$5,028,019
Net Gain/Loss	$284,421

Functional expenses
Accounting Fees	$32,242
Advertising & Promotion	$0
Information Technology Expenses	$209,050
Insurance Expenses	$23,878
Interest Expenses	$0
Investment Management Fees	$0
Legal Fees	$42,133
Pension Plan Contributions	$75,398
Professional Fundraising Expenses	$127,772

LUNG CANCER RESEARCH FOUNDATION

Balance sheet

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: Download Data

Assets	Jan 01, 2008	Dec 31, 2008	Change
Contributions	$948,959
Cash & Equivalents	$958,186	$979,344	$21,158
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$15,000	$35,000	$20,000
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$0	$3,000	$3,000
Total Assets	$973,186	$1,017,344	$44,158

Liabilities	Jan 01, 2008	Dec 31, 2008	Change
Accounts Payable	$13,371	$17,452	$4,081
Grants Payable	$0	$75,000	$75,000
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$13,371	$92,452	$79,081

Fund balance	Jan 01, 2008	Dec 31, 2008	Change
Temporarily Restricted Net Assets	$0	$0	$0
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$0	$0
Unrestricted Net Assets	$0	$0	$0
Net Assets	$959,815	$924,892	($34,923)

Assets	Jan 01, 2009	Dec 31, 2009	Change
Contributions	$902,165
Cash & Equivalents	$979,344	$1,055,353	$76,009
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$35,000	$10,000	($25,000)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$3,000	$10,738	$7,738
Total Assets	$1,017,344	$1,076,091	$58,747

Liabilities	Jan 01, 2009	Dec 31, 2009	Change
Accounts Payable	$17,452	$12,455	($4,997)
Grants Payable	$75,000	$0	($75,000)
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$92,452	$12,455	($79,997)

Fund balance	Jan 01, 2009	Dec 31, 2009	Change
Temporarily Restricted Net Assets	$0	$0	$0
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$0	$0
Unrestricted Net Assets	$0	$0	$0
Net Assets	$924,892	$1,063,636	$138,744

Assets	Jan 01, 2010	Dec 31, 2010	Change
Contributions	$2,337,677
Cash & Equivalents	$1,055,353	$1,476,878	$421,525
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$10,000	$1,150,000	$1,140,000
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$10,738	$8,951	($1,787)
Total Assets	$1,076,091	$2,635,829	$1,559,738

Liabilities	Jan 01, 2010	Dec 31, 2010	Change
Accounts Payable	$12,455	$15,750	$3,295
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$12,455	$15,750	$3,295

Fund balance	Jan 01, 2010	Dec 31, 2010	Change
Temporarily Restricted Net Assets	$0	$1,250,000	$1,250,000
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$0	$1,250,000	$1,250,000
Unrestricted Net Assets	$1,063,636	$1,370,079	$306,443
Net Assets	$1,063,636	$2,620,079	$1,556,443

Assets	Jan 01, 2011	Dec 31, 2011	Change
Contributions	$387,739
Cash & Equivalents	$1,476,878	$1,524,164	$47,286
Accounts Receivable	$0	$0	$0
Pledges & Grants Receivable	$1,150,000	$561,200	($588,800)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$0	$0	$0
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$0	$0	$0
Other	$8,951	$4,700	($4,251)
Total Assets	$2,635,829	$2,090,064	($545,765)

Liabilities	Jan 01, 2011	Dec 31, 2011	Change
Accounts Payable	$15,750	$83,619	$67,869
Grants Payable	$0	$0	$0
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$15,750	$83,619	$67,869

LUNG CANCER RESEARCH FOUNDATION

Financial trends analysis Glossary & formula definitions

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990

This snapshot of LUNG CANCER RESEARCH FOUNDATION’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Fiscal year: Jan 01 - Dec 31 View full report Download data

Business model indicators

Profitability	2016	2017	2018	2019	2020
Unrestricted surplus (deficit) before depreciation	-$574,275	$1,255,494	-$697,921	-$236,005	$333,944
As % of expenses	-13.8%	27.7%	-11.1%	-4.3%	6.7%
Unrestricted surplus (deficit) after depreciation	-$590,193	$1,236,550	-$721,297	-$276,068	$272,510
As % of expenses	-14.1%	27.2%	-11.4%	-5.0%	5.4%

Revenue composition
Total revenue (unrestricted & restricted)	$3,698,071	$4,633,495	$5,524,578	$5,337,706	$5,312,440
Total revenue, % change over prior year	-1.1%	25.3%	19.2%	-3.4%	-0.5%
Program services revenue	0.0%	0.0%	0.0%	0.0%	0.0%
Membership dues	0.0%	0.0%	0.0%	0.0%	0.0%
Investment income	0.1%	0.9%	0.1%	0.1%	0.0%
Government grants	0.0%	0.0%	0.0%	0.0%	8.3%
All other grants and contributions	99.9%	98.5%	99.9%	99.8%	91.0%
Other revenue	0.0%	0.6%	0.0%	0.2%	0.7%

Expense composition
Total expenses before depreciation	$4,171,082	$4,535,302	$6,303,335	$5,498,711	$4,966,585
Total expenses, % change over prior year	17.7%	8.7%	39.0%	-12.8%	-9.7%
Personnel	33.8%	43.9%	44.8%	55.3%	52.7%
Professional fees	3.0%	5.4%	6.6%	2.9%	5.7%
Occupancy	4.0%	4.4%	4.3%	4.1%	4.4%
Interest	0.0%	0.0%	0.0%	0.0%	0.0%
Pass-through	52.1%	37.8%	30.9%	21.8%	24.0%
All other expenses	7.0%	8.4%	13.4%	15.9%	13.3%

Full cost components (estimated)	2016	2017	2018	2019	2020
Total expenses (after depreciation)	$4,187,000	$4,554,246	$6,326,711	$5,538,774	$5,028,019
One month of savings	$347,590	$377,942	$525,278	$458,226	$413,882
Debt principal payment	$0	$0	$0	$0	$0
Fixed asset additions	$20,497	$0	$0	$152,218	$0
Total full costs (estimated)	$4,555,087	$4,932,188	$6,851,989	$6,149,218	$5,441,901

Capital structure indicators

Liquidity	2016	2017	2018	2019	2020
Months of cash	7.5	9.4	8.7	7.7	9.4
Months of cash and investments	7.5	12.6	8.7	7.7	9.4
Months of estimated liquid unrestricted net assets	5.9	8.7	4.9	4.8	6.1

Balance sheet composition	2016	2017	2018	2019	2020
Cash	$2,595,162	$3,558,997	$4,575,498	$3,511,726	$3,910,801
Investments	$25,475	$1,186,083	$0	$0	$0
Receivables	$575,085	$486,849	$317,260	$288,800	$551,477
Gross land, buildings, equipment (LBE)	$74,564	$173,384	$185,505	$337,723	$340,522
Accumulated depreciation (as a % of LBE)	40.2%	78.3%	85.8%	59.0%	76.5%
Liabilities (as a % of assets)	33.5%	37.5%	48.0%	39.3%	41.2%
Unrestricted net assets	$2,095,628	$3,332,178	$2,610,881	$2,334,813	$2,607,323
Temporarily restricted net assets	$101,250	$49,500	$0	N/A	N/A
Permanently restricted net assets	$0	$0	$0	N/A	N/A
Total restricted net assets	$101,250	$49,500	$0	$75,000	$86,911
Total net assets	$2,196,878	$3,381,678	$2,610,881	$2,409,813	$2,694,234

Key data checks

Key data checks	2016	2017	2018	2019	2020
Material data errors	No	No	No	No	No

Operations

The people, governance practices, and partners that make the organization tick.

Documents

Letter of Determination

Form 1023/1024 is not available for this organization

Executive Director

Dennis Chillemi

LinkedIn profile

Dennis P. Chillemi is the Executive Director of the Lung Cancer Research Foundation (LCRF) and has held this role since October 2018. LCRF is the largest lung cancer focused foundation in the US supporting lung cancer research. Its mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer. In his role as Executive Director, Mr. Chillemi is focused on growing the impact of the organization on a national level, drive awareness and raise much needed funds to support cutting edge research in lung cancer. Prior to joining the Lung Cancer Research Foundation, Mr. Chillemi served as the Senior Director of Development at the Lymphoma Research Foundation, where he was responsible for the development and implementation of national strategic plans for all fundraising activities, including corporate sponsorship, distinguished events and planned gifts. Prior to joining the Lymphoma Research Foundation, Chillemi served as the

Number of employees

Source: IRS Form 990

LUNG CANCER RESEARCH FOUNDATION

Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Compensation

Other

Show data for fiscal year

Compensation data

Download up to 5 most recent years of officer and director compensation data for this organization

LUNG CANCER RESEARCH FOUNDATION

Highest paid employees

SOURCE: IRS Form 990

Compensation

Other

Show data for fiscal year

Compensation data

Download up to 5 most recent years of highest paid employee data for this organization

LUNG CANCER RESEARCH FOUNDATION

Board of directors
as of 03/11/2022

SOURCE: Self-reported by organization

Board of directors data

Download the most recent year of board of directors data for this organization

Board chair

Reina Honts

Mary Ann Tighe

Joan H. Schiller, MD

Aaron M. Tighe

Raymond E. Chalmé

Peter Fry

Jill Furman

Ronald D. Sernau

Rose Ann Weinstein

Katerina Politi

Brendon Stiles

Bruce Dunbar

Scott Morris

Coleen Conner-Ziegler

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

Board orientation and education
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
CEO oversight
Has the board conducted a formal, written assessment of the chief executive within the past year ? No
Ethics and transparency
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
Board composition
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
Board performance
Has the board conducted a formal, written self-assessment of its performance within the past three years? Not applicable

Organizational demographics

SOURCE: Self-reported; last updated 3/11/2022

Candid has made improvements to the race and ethnicity options.

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.

Leadership

The organization's leader identifies as:

Race & ethnicity

White/Caucasian/European

Gender identity

Male, Not transgender (cisgender)

Sexual orientation

Heterosexual or straight

Disability status

Person without a disability

Race & ethnicity

Gender identity

Sexual orientation

Disability

Equity strategies

Last updated: 04/14/2021

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

Data

We review compensation data across the organization (and by staff levels) to identify disparities by race.
We ask team members to identify racial disparities in their programs and / or portfolios.
We analyze disaggregated data and root causes of race disparities that impact the organization's programs, portfolios, and the populations served.
We disaggregate data to adjust programming goals to keep pace with changing needs of the communities we support.
We employ non-traditional ways of gathering feedback on programs and trainings, which may include interviews, roundtables, and external reviews with/by community stakeholders.
We have long-term strategic plans and measurable goals for creating a culture such that one’s race identity has no influence on how they fare within the organization.

Policies and processes

We seek individuals from various race backgrounds for board and executive director/CEO positions within our organization.
We have community representation at the board level, either on the board itself or through a community advisory board.
We help senior leadership understand how to be inclusive leaders with learning approaches that emphasize reflection, iteration, and adaptability.
We engage everyone, from the board to staff levels of the organization, in race equity work and ensure that individuals understand their roles in creating culture such that one’s race identity has no influence on how they fare within the organization.

Contractors

Fiscal year ending

Professional fundraisers

Fiscal year ending

SOURCE: IRS Form 990 Schedule G

Solicitation activities

Gross receipts from fundraising

Retained by organization

Paid to fundraiser

LUNG CANCER RESEARCH FOUNDATION

Living. Breathing. Science.

Mission

Is this your nonprofit?

Programs and results

Reports and documents

What we aim to solve

Our programs

Scientific Grant Program

Patient Education & Outreach

Where we work

Affiliations & memberships

Our results

Evaluation documents

Number of research studies funded

Totals By Year

Population(s) Served

Related Program

Type of Metric

Direction of Success

Context Notes

Median grant amount

Totals By Year

Population(s) Served

Related Program

Type of Metric

Direction of Success

Context Notes

Total dollar amount of grants awarded

Totals By Year

Population(s) Served

Related Program

Type of Metric

Direction of Success

Context Notes

Number of organizations applying for grants

Totals By Year

Population(s) Served

Related Program

Type of Metric

Direction of Success

Context Notes

Number of unique website visitors

Totals By Year

Population(s) Served

Related Program

Type of Metric

Direction of Success

Context Notes

Our Sustainable Development Goals

Goals & Strategy

Charting impact

What is the organization aiming to accomplish?

What are the organization's key strategies for making this happen?

What are the organization's capabilities for doing this?

What have they accomplished so far and what's next?

How we listen

Financials

Financial documents

Revenue vs. expenses: breakdown

Liquidity in 2020 info

2.07

Months of cash in 2020 info

9.4

Fringe rate in 2020 info

25%

Funding sources info

Assets & liabilities info

Financial data

Digitizing IRS form 990 data

LUNG CANCER RESEARCH FOUNDATION

LUNG CANCER RESEARCH FOUNDATION

LUNG CANCER RESEARCH FOUNDATION

Business model indicators

Capital structure indicators

Key data checks

Operations

Documents

Executive Director

Dennis Chillemi

Liquidity in 2020

Months of cash in 2020

Fringe rate in 2020

Funding sources

Assets & liabilities